Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

ABSTRACT:

Background

Clinical drug trials in patients with heart failure and preserved ejection fraction have failed to demonstrate improvements in mortality.

Methods

We systematically searched Medline, Embase and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCT) assessing pharmacological treatments in patients with heart failure with left ventricular (LV) ejection fraction≥40% from January 1996 to May 2016. The primary efficacy outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, heart failure hospitalisation, exercise capacity (6-min walk distance, exercise duration, VO₂ max), quality of life and biomarkers (B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide). Random-effects models we

SUBMITTER: Zheng SL 

PROVIDER: S-EPMC5861385 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature